Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2015 3
2016 2
2017 8
2018 3
2019 6
2020 28
2021 63
2022 61
2023 91
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Results by year

Filters applied: . Clear all
The following terms were ignored: "", OR
Quoted phrases not found in phrase index: "1350653-20-1"
Page 1
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM; VICTORIA Study Group. Armstrong PW, et al. N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28. N Engl J Med. 2020. PMID: 32222134 Free article. Clinical Trial.
A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure (hazard ratio, 0.90; 95% CI, 0.81 to 1.00). ...Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group …
A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart fai …
Heart Failure With Reduced Ejection Fraction: A Review.
Murphy SP, Ibrahim NE, Januzzi JL Jr. Murphy SP, et al. JAMA. 2020 Aug 4;324(5):488-504. doi: 10.1001/jama.2020.10262. JAMA. 2020. PMID: 32749493 Review.
More recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors have further improved disease outcomes, significantly reducing cardiovascular and all-cause mortality irrespective of diabetes status, and vericiguat, a soluble guanylate cyclase stimulator, reduces heart fai …
More recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors have further improved disease outcomes, significantly reducing cardiovascul …
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P, Anand IS, Lam CSP, Voors AA. Tromp J, et al. JACC Heart Fail. 2022 Feb;10(2):73-84. doi: 10.1016/j.jchf.2021.09.004. Epub 2021 Dec 8. JACC Heart Fail. 2022. PMID: 34895860 Free article.
We included angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers (BB), mineralocorticoid receptor antagonists (MRAs), digoxin, hydralazine-isosorbide dinitrate, ivabradine, angiotensin receptor-neprilysin inhibitors (ARNi), sodium glucose cotrans …
We included angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers (BB), mineralocorticoid receptor antagoni …
Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.
Beldhuis IE, Lam CSP, Testani JM, Voors AA, Van Spall HGC, Ter Maaten JM, Damman K. Beldhuis IE, et al. Circulation. 2022 Mar;145(9):693-712. doi: 10.1161/CIRCULATIONAHA.121.052792. Epub 2022 Feb 28. Circulation. 2022. PMID: 35226558 Free PMC article. Review.
For more severe CKD (stage 4), there is evidence of safety and efficacy of sodium glucose cotransporter 2 inhibitors, and to a lesser extent, angiotensin-converting enzyme inhibitors, vericiguat, digoxin and omecamtiv mecarbil, although this evidence is restricted to impro …
For more severe CKD (stage 4), there is evidence of safety and efficacy of sodium glucose cotransporter 2 inhibitors, and to a lesser extent …
Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
Kang C, Lamb YN. Kang C, et al. Am J Cardiovasc Drugs. 2022 Jul;22(4):451-459. doi: 10.1007/s40256-022-00538-5. Epub 2022 May 28. Am J Cardiovasc Drugs. 2022. PMID: 35624347 Review.
The risk of all-cause mortality or first HHF (secondary composite endpoint) and the total number of HHF were also statistically significantly reduced by vericiguat therapy. Vericiguat showed no benefit with respect to the primary endpoint in a subgroup of patients w …
The risk of all-cause mortality or first HHF (secondary composite endpoint) and the total number of HHF were also statistically significantl …
[Update on diagnostics and treatment of heart failure].
Wintrich J, Berger AK, Bewarder Y, Emrich I, Slawik J, Böhm M. Wintrich J, et al. Herz. 2022 Aug;47(4):340-353. doi: 10.1007/s00059-021-05062-x. Epub 2021 Aug 31. Herz. 2022. PMID: 34463784 Free PMC article. Review. German.
Efficacy and safety of vericiguat in heart failure: a meta-analysis.
Ma J, Guo S, Jiang H, Li B. Ma J, et al. J Int Med Res. 2023 Mar;51(3):3000605231159333. doi: 10.1177/03000605231159333. J Int Med Res. 2023. PMID: 36896460 Free PMC article. Review.
OBJECTIVE: This study aimed to investigate the safety and efficacy of vericiguat in patients with heart failure (HF). METHODS: We conducted a comprehensive literature review of the PubMed, Embase, and Cochrane Library databases up to 14 December 2022 for studies comparing …
OBJECTIVE: This study aimed to investigate the safety and efficacy of vericiguat in patients with heart failure (HF). METHODS: We con …
Cost effectiveness analyses of pharmacological treatments in heart failure.
Lim AH, Abdul Rahim N, Zhao J, Cheung SYA, Lin YW. Lim AH, et al. Front Pharmacol. 2022 Sep 5;13:919974. doi: 10.3389/fphar.2022.919974. eCollection 2022. Front Pharmacol. 2022. PMID: 36133814 Free PMC article. Review.
However, there is a lack of clinical or real-world data regarding whether vericiguat would be prescribed on top of newer treatments or in lieu of them. ...This review aims to evaluate evidence and cost effectiveness studies in more recent HF drugs i.e., SGLT2i, ARNi, ivabr …
However, there is a lack of clinical or real-world data regarding whether vericiguat would be prescribed on top of newer treatments o …
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, She L, Vlajnic V, Carvalho F, Bamber L, Blaustein RO, Roessig L, Butler J; VITALITY-HFpEF Study Group. Armstrong PW, et al. JAMA. 2020 Oct 20;324(15):1512-1521. doi: 10.1001/jama.2020.15922. JAMA. 2020. PMID: 33079152 Free PMC article. Clinical Trial.
The least-squares mean difference in scores between the 15-mg/d vericiguat and placebo groups was -1.5 (95% CI, -5.5 to 2.5; P = .47) and between the 10-mg/d vericiguat and placebo groups was -0.5 (95% CI, -4.6 to 3.5; P = .80). ...The proportions of patients who ex …
The least-squares mean difference in scores between the 15-mg/d vericiguat and placebo groups was -1.5 (95% CI, -5.5 to 2.5; P = .47) …
Current and emerging drug targets in heart failure treatment.
Ghionzoli N, Gentile F, Del Franco AM, Castiglione V, Aimo A, Giannoni A, Burchielli S, Cameli M, Emdin M, Vergaro G. Ghionzoli N, et al. Heart Fail Rev. 2022 Jul;27(4):1119-1136. doi: 10.1007/s10741-021-10137-2. Epub 2021 Jul 17. Heart Fail Rev. 2022. PMID: 34273070 Free PMC article. Review.
Among them, drugs acting directly at a second messenger level, such as the soluble guanylate cyclase stimulator vericiguat, or other addressing myocardial energetics and mitochondrial function, such as elamipretide or omecamtiv-mecarbil, will likely change the therapeutic …
Among them, drugs acting directly at a second messenger level, such as the soluble guanylate cyclase stimulator vericiguat, or other …
262 results